Real-World Data to Inform Lung Treatment in the Future
Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.
Robert Coleman, MD, FACOG, FACS, chief scientific officer for US Oncology Research, supported by McKesson, and an oncologist with Texas Oncology, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented during the Association of Community Cancer Centers (ACCC) Annual Meeting.
In lung cancer, there is always a need for research, says Coleman. But there are certain subgroups for which oncologists need more information to provide optimal care. This data will likely come from real-world research rather than clinical trial research. This is mainly because of the restrictive eligibility criteria of some clinical trials.
The presence of comorbidities, age, performance status, and other factors play a role in how patients respond to therapy, Coleman notes. With real-world research through programs like MyLung and others, the lung cancer field has a better chance of understanding how best to treat the various subgroups of patients.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
